Search

Your search for "qsam" returned the following results.
Filter Results:
InvestorNewsBreaks

InvestorNewsBreaks – QSAM Biosciences Inc. (QSAM) Signs Definitive Agreement, Plan of Merger with Telix Pharmaceuticals

February 8, 2024

QSAM Biosciences (OTCQB: QSAM), a clinical-stage biotechnology company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam), for the treatment of bone cancer and other diseases and conditions, has signed a definitive agreement and plan of merger providing for the acquisition of the company by Telix Pharmaceuticals Limited (ASX: TLX). According to the announcement, QSAM stockholders will receive $33.1 […]

InvestorNewsBreaks

InvestorNewsBreaks – QSAM Biosciences Inc. (QSAM) Inks Acquisition Term Sheet with Telix Pharmaceuticals

November 14, 2023

QSAM Biosciences (OTCQB: QSAM), a clinical-stage biotechnology company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam), for the treatment of bone cancer and other diseases and conditions, has signed a nonbinding term sheet with Telix Pharmaceuticals (U.S.) Inc., a subsidiary of Telix Pharmaceuticals Limited. Telix is a biopharmaceutical company focused on the development and commercialization of diagnostic […]

InvestorNewsBreaks

InvestorNewsBreaks – QSAM Biosciences Inc. (QSAM) Issues Update on Progress, Preliminary Clinical Data for Phase 1 CycloSam(R) Trial

August 16, 2023

QSAM Biosciences (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (“CycloSam(R)”), for the treatment of bone cancer and related diseases, today issued a letter to its shareholders. In the letter, the company’s Executive Chairman C. Richard Piazza and CEO Douglas Baum, who are also co-founders of QSAM, provided an update on the progress […]

InvestorNewsBreaks

InvestorNewsBreaks – QSAM Biosciences Inc. (QSAM) Adds UT-Austin to Supply Chain, Expanding Capacity for CycloSam(R) Production

June 14, 2023

QSAM Biosciences (OTCQB: QSAM) is a clinical stage biotechnology company developing next-generation therapeutic radiopharmaceuticals for the treatment of cancer and other diseases and conditions. The company today announced the qualification and addition of the nuclear reactor at the University of Texas at Austin to its supply chain for the production of Samarium-153, the active radioisotope […]

InvestorNewsBreaks

InvestorNewsBreaks – QSAM Biosciences Inc. (QSAM) Adds Clinical Trial Site for CycloSam(R) Study

May 23, 2023

QSAM Biosciences (OTCQB: QSAM), a clinical stage biotechnology company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam), for the treatment of bone cancer and other diseases and conditions, has added a site for its phase 1 study. The company announced that the Insight Research Institute at the Institute Hospital and Medical Center in Chicago will be […]

InvestorNewsBreaks

InvestorNewsBreaks – QSAM Biosciences Inc. (QSAM) Inks Supply Agreement with Leading Nuclear Medicine Pharmacy Network

May 16, 2023

QSAM Biosciences (OTCQB: QSAM), a clinical stage biotechnology company developing next-generation therapeutic radiopharmaceuticals, has announced a partnership with RLS (USA) Inc., the third-largest nuclear medicine pharmacy network in the country. The two companies have a commercial supply and clinical dose preparation agreement for the therapeutic radiopharmaceutical drug candidate CycloSam(R) (Samarium-153 DOTMP), a promising clinical-stage treatment for metastatic and […]

InvestorNewsBreaks

InvestorNewsBreaks – QSAM Biosciences Inc. (QSAM) Granted European Patent for Clinical-Stage Radiopharmaceutical Drug Candidate

April 26, 2023

QSAM Biosciences (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP, or CycloSam(R), for the treatment of bone cancer and other diseases, announced been “allowed” a key patent by the European Patent Office (“EPO”). According to the announcement, the patent protects the use of “lower specific activity” Samarium-153 in conjunction with the treatment of […]

InvestorNewsBreaks

InvestorNewsBreaks – QSAM Biosciences Inc. (QSAM) Phase 1 CycloSam(R) Study Ready to Open Cohort 2 Enrollment

April 5, 2023

QSAM Biosciences (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP, or CycloSam(R), for the treatment of bone cancer and related diseases and conditions, has announced enrollment for its phase 1 study of CycloSam(R) in the treatment of bone cancer. The enrollment is for cohort 2, the second grouping of participants, after cohort 1 was completed […]

InvestorNewsBreaks

InvestorNewsBreaks – QSAM Biosciences Inc. (QSAM) to Provide Clinical Trial Updates at Emerging Growth Conference

March 20, 2023

QSAM Biosciences (OTCQB: QSAM) is developing next generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (“CycloSam(R)”), for the treatment of bone cancer and related diseases and conditions. The company today announced that it was invited to provide updates on its clinical trial evaluating CycloSam for the treatment of metastatic bone cancer at the upcoming Emerging Growth Conference. Scheduled […]

InvestorNewsBreaks

InvestorNewsBreaks – QSAM Biosciences Inc. (QSAM) Receives FDA Clearance to Expand Enrollment Criteria in Phase 1 Study of CycloSam(R)

March 8, 2023

QSAM Biosciences (OTCQB: QSAM) is developing next generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam(R)), for the treatment of bone cancer and related diseases and conditions. The company today announced clearance, by the U.S. Food & Drug Administration (“FDA”), of its amended clinical trial protocol increasing the maximum age of participants to 75 years old from the […]

InvestorNewsBreaks

InvestorNewsBreaks – QSAM Biosciences Inc. (QSAM) Featured in New Goldman Small Cap Research Report

March 1, 2023

QSAM Biosciences (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP, or CycloSam(R), for the treatment of bone cancer and related diseases and conditions, is spotlighted in a new opportunity research report released by Goldman Small Cap Research. A stock market research company specializing in the small cap and microcap sectors, Goldman reviewed QSAM’s […]

InvestorNewsBreaks

InvestorNewsBreaks – QSAM Biosciences Inc. (QSAM) Announces Completion of Enrollment for Phase 1 CycloSam Study

February 28, 2023

QSAM Biosciences (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP, or CycloSam(R), for the treatment of bone cancer and related diseases and conditions, has completed enrollment in its first participant grouping, or cohort, for its upcoming phase 1 study. The study is designed to evaluate CycloSam in the treatment of bone cancer. The […]

InvestorNewsBreaks

InvestorNewsBreaks – QSAM Biosciences Inc. (QSAM) Adds New Trial Site to Expand Study of CycloSam(R) for Bone Cancer

February 22, 2023

QSAM Biosciences (OTCQB: QSAM), a company developing next generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam(R)), for the treatment of bone cancer and related diseases and conditions, today announced the addition of the Ellis Fischel Cancer Center at the University of Missouri School of Medicine as an upcoming clinical trial site. The trial will soon begin enrolling […]

InvestorNewsBreaks

InvestorNewsBreaks – QSAM Biosciences Inc. (QSAM) to Present at Emerging Growth Conference

January 23, 2023

QSAM Biosciences (OTCQB: QSAM) is developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam(R)), for the treatment of bone cancer and related diseases and conditions. The company today announced that it has been invited to present at the Emerging Growth Conference at 10:15 a.m. ET on Wednesday, Jan. 25, 2023. Leading QSAM’s presentation will be the company’s […]

InvestorNewsBreaks

InvestorNewsBreaks – QSAM Biosciences Inc. (QSAM) Releases Shareholder Letter Outlining 2022 Updates, 2023 Milestone Goals

January 10, 2023

QSAM Biosciences (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP, or CycloSam(R), for the treatment of bone cancer and related diseases, has provided key updates and milestone goals in a shareholder letter; the letter is from QSAM Biosciences executive chair and cofounder C. Richard Piazza and CEO and cofounder Douglas Baum. The letter noted […]

InvestorNewsBreaks

InvestorNewsBreaks – QSAM Biosciences Inc. (QSAM) Announces Q3 2022 Results, Provides Corporate Update

November 15, 2022

QSAM Biosciences (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam(R)), for the treatment of bone cancer and related diseases, today announced financial results for the third quarter ended Sept. 30, 2022, and provided a corporate update. “Initial, preliminary data from our second patient dosed with CycloSam continues to show positive signals in […]

InvestorNewsBreaks

InvestorNewsBreaks – QSAM Biosciences Inc. (QSAM) Announces Approval of Second Clinical Trial Site for Phase 1 Study

October 26, 2022

QSAM Biosciences (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP, or CycloSam(R), for the treatment of bone cancer and related diseases, has added Rutgers Cancer Institute of New Jersey (“RCINJ”) as a clinical trial site for its phase 1 CycloSam study. RCINJ has been approved to begin enrolling patients into the study, which […]

InvestorNewsBreaks

InvestorNewsBreaks – QSAM Biosciences Inc. (QSAM) Working to Make a Difference in Underserved Patient Populations

September 30, 2022

QSAM Biosciences (OTCQB: QSAM) is a clinical-stage biotechnology company focused on developing and bringing to market targeted therapeutic radiopharmaceuticals and advancing the fight against cancer, including the underserved pediatric population. “With the overall incidence of childhood cancer on the rise, the work of QSAM is becoming increasingly important… According to Children’s Cancer Cause, in 2022, […]

News Articles

QSAM Biosciences Inc. (QSAM) Working to Halt, Regress Bone Tumors in Children Through Therapeutic Radiopharmaceuticals

September 20, 2022

Overall incidence of childhood cancer is on the increase, averaging 0.8% increase per year since 1975, reports leading advocacy organization QSAM developing therapeutic radiopharmaceuticals as safer, more efficacious alternatives to address unmet medical needs, underserved patient populations Company creating pipeline of novel radiotherapeutics to serve multiple indications with its lead product, CycloSam With the overall […]

InvestorNewsBreaks

InvestorNewsBreaks – QSAM Biosciences Inc. (QSAM) Receives ‘Marketable Advantage’ Toward Manufacturing, Supply Chain of CycloSam(R)

August 25, 2022

QSAM Biosciences (OTCQB: QSAM) recently received a key patent for its exclusive radiopharmaceutical drug candidate, CycloSam(R), from the U.S. Patent & Trademark Office. “The patent protects how CycloSam is formulated and prepared, namely by using a nonradioactive kit that can be delivered and stored local to the administration site and provides for high purity in […]

InvestorNewsBreaks

InvestorNewsBreaks – QSAM Biosciences Inc. (OTCQB: QSAM) Releases Q2 2022 Financial Report, Corporate Update

August 16, 2022

QSAM Biosciences (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP, or CycloSam(R), for the treatment of bone cancer and related diseases, has reported on its financial results for Q2, the period ended June 30, 2022; the company also noted that progress has been shown in its phase 1 clinical program designed to evaluate […]

InvestorNewsBreaks

InvestorNewsBreaks – QSAM Biosciences Inc. (QSAM) Targeting Significant Unmet Medical Need with CycloSam(R)

July 28, 2022

QSAM Biosciences (OTCQB: QSAM) is a company developing a new class of drugs called radiopharmaceuticals that deliver radiation therapy directly and specifically to cancer cells. The company’s lead drug candidate, CycloSam(R), is a clinical-stage bone-seeking radiopharmaceutical designed to deliver targeted radiation safely and precisely to tumors in the bone. “QSAM is leading the charge to […]

InvestorNewsBreaks

InvestorNewsBreaks – Why QSAM Biosciences Inc. (QSAM) Is ‘One to Watch’

July 22, 2022

QSAM Biosciences (OTCQB: QSAM), a clinical-stage biotechnology company, is focused on bringing to market targeted therapeutic radiopharmaceuticals. “The company is committed to advancing the fight against cancer through the discovery, development and delivery of effective treatment options for adult and pediatric patients,” a recent article reads. “CycloSam(R), QSAM Biosciences’ initial technology, is a clinical-stage bone […]

News Articles

QSAM Biosciences Inc. (QSAM) Marks Milestone with Dosing of First Patient in CycloSam Clinical Trial

July 19, 2022

Treating patients with primary or secondary bone cancer remains goal, says company CEO Radiopharmaceuticals is a new class of drugs that delivers radiation therapy directly to cancer cells QSAM is working to develop CycloSam(R) as a breakthrough therapeutic for adult and pediatric bone cancer patients QSAM Biosciences (OTCQB: QSAM), a company developing a new class of […]

InvestorNewsBreaks

InvestorNewsBreaks – QSAM Biosciences Inc. (QSAM) Expands IP Estate with Receipt of Third US Patent for CycloSam(R)

July 13, 2022

QSAM Biosciences (OTCQB: QSAM) is a company developing next-generation targeted therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (“CycloSam(R)”), for the treatment of cancer and related diseases. The company today announced that the United States Patent & Trademark Office has granted a key patent protecting how CycloSam(R) is formulated and prepared, namely by using a nonradioactive kit that can […]

Press Releases

QSAM Biosciences Receives Third U.S. Patent for Clinical-Stage Radiopharmaceutical Drug Candidate CycloSam®

July 13, 2022

AUSTIN, Texas, July 13, 2022 (GLOBE NEWSWIRE) — via Investorwire — QSAM Biosciences Inc. (OTCQB: QSAM) (the “Company”), a company developing next-generation targeted therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®), for the treatment of cancer and related diseases, announces today that the United States Patent & Trademark Office has granted a key patent protecting how CycloSam® is formulated and prepared, […]

News Articles

QSAM Biosciences Inc. (QSAM) Is ‘One to Watch’

July 7, 2022

QSAM Biosciences Inc. is committed to advancing the fight against cancer through the discovery, development and delivery of effective treatment options for adult and pediatric patients CycloSam(R), QSAM Biosciences’ initial technology, is a clinical-stage bone targeting radiopharmaceutical being evaluated for multiple indications CycloSam has been shown to cause significantly less buildup of long-lived radionuclidic impurities […]

No ResultsNo content matches your search/filter.

 

 

 

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).